US EditionPublished • loading... • Updated
Valitor Presents Preclinical Datasets on the Potential of its Anti-VEGF Therapy Dosed Twice Yearly for Wet AMD
Summary by Eyewire+
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Valitor Presents Preclinical Datasets on the Potential of its Anti-VEGF Therapy Dosed Twice Yearly for Wet AMD
Valitor announced data from VLTR-559, its long-acting anti-VEGF biologic in development for its wet age-related macular degeneration (AMD) treatment, and its multivalent polymer (MVP) technology platform, were presented at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Salt Lake City, Utah. “VLTR-559 was developed using our pioneering MVP technology platform and was designed to be an anti-VEGF therapy with…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
